Related by context. All words. (Click for frequent words.) 76 Randomised 75 multicenter randomized controlled 75 multicentre randomized controlled 75 multicentre randomized 73 cluster randomized controlled 72 randomized crossover 72 NSABP B 71 EURIDIS 71 registrational Phase 71 multicentre prospective 71 blinded randomized controlled 71 multicenter randomized clinical 70 multicenter randomized placebo controlled 70 nonrandomized 69 trials RCTs 69 ACCORD Lipid 69 thorough QT 69 prospective randomized controlled 69 phase IIIb 69 Intervention Effectiveness 69 Multicenter 69 double blinded randomized 68 Placebo controlled 68 randomized multicenter trial 68 randomized blinded 68 prospective multicentre 68 multicenter prospective 68 PREVENT IV 68 STRIDE PD 68 Carotid Revascularization Endarterectomy vs. 68 Refractory Angina 68 unfractionated heparin UFH 67 EXPLORE Xa 67 RE MODEL 67 Initiated Phase 67 Phase IIb III 67 blinded randomized placebo controlled 67 dose escalation phase 67 CHARM Added 67 RE LY ® 67 placebo controlled clinical 67 multicenter randomized 67 Randomized Evaluation 67 ONTARGET 67 ADMIRE HF 67 Randomized 67 CALERIE 66 relapsed MM 66 COR Diabetes 66 randomized controlled clinical 66 randomized multicenter 66 prospective nonrandomized 66 randomized multicentre 66 Long Lesion 66 BRIM3 66 GOUT 66 RE LY 66 Intervention Effectiveness CATIE 66 multicenter multinational 66 pharmacokinetics PK 66 HORIZONS AMI 66 ACTIVE W 66 Phase IIIb clinical 66 CLARITY TIMI 66 prospective randomized multicenter 66 NCT# ClinicalTrials.gov 65 landmark ATHENA 65 randomized controlled multicenter 65 RECORD1 65 galiximab 65 prospectively randomized 65 CARE HF 65 dose escalation clinical 65 epoetin alpha 65 oral rivaroxaban 65 HYVET 65 Primary endpoints 65 multicentre 65 Spine Patient Outcomes 65 CHAMPION PCI 65 Decompensated Heart Failure 65 ADONIS 65 blinded randomized 65 NO# [002] 65 Coronary Artery Bypass Graft 65 meta regression 65 Prostate AdenoCarcinoma Treatment 65 prospective multicenter 65 Phase 1a clinical 65 PFO migraine 65 CA9 SCAN 65 MADIT 65 ENESTnd 65 placebo controlled randomized 65 MEND CABG 65 REALITY Trial 65 randomized Phase IIb 65 randomized discontinuation 65 multicenter clinical 64 phase IIb III 64 Multicenter Automatic Defibrillator Implantation 64 Multiple Ascending Dose 64 GISSI HF 64 blind randomized controlled 64 confirmatory clinical 64 Clinical Antipsychotic Trials 64 Subgroup analysis 64 multicenter Phase II 64 dose atorvastatin 64 Myocardial Infarction Study 64 ExTRACT TIMI 64 placebo controlled multicenter 64 TMC# C# 64 TAXUS ATLAS 64 Phase IIA 64 IMPACT DCM 64 CIMZIA TM certolizumab pegol 64 longitudinal cohort study 64 Phase 2b kidney transplant 64 CURRENT OASIS 7 64 Randomized placebo controlled 64 ASTEROID 64 Meta analyzes 64 observational cohort 64 Secondary efficacy endpoints 64 BARI 2D 64 multicentre randomized double 64 TAXUS VI 64 Randomized Phase II 64 PRoFESS 64 Fondaparinux 64 Pharmacologic 64 Phase Ib IIa 64 prospective observational studies 64 fosbretabulin 64 HF ACTION 64 ACCOMPLISH 63 Phase Ib clinical 63 orally inhaled migraine 63 carotid artery stenting CAS 63 Pharmacodynamic 63 SIMPADICO 63 Edge STudy 63 Echocardiographic 63 HCV SPRINT 63 Phase Ib II 63 Randomized Double blind 63 subanalysis 63 Phase III multicenter 63 BRIM2 63 PRIMO CABG 63 Val HeFT 63 pain palliation 63 randomized clinical 63 ENGAGE AF TIMI 63 carotid endarterectomy CEA 63 VADT 63 Randomized trials 63 NEVO RES 63 Zemplar Capsules 63 ROCKET AF 63 EmbraceAC 63 Stenting Trial CREST 63 Pemetrexed 63 pharmacokinetic pharmacodynamic PK PD 63 National Emphysema Treatment 63 Cardiotoxicity 63 Randomized Study 63 treatment naive genotype 63 CATIE AD 63 Bayer HealthCare Onyx Pharmaceuticals 63 Prospective Randomized 63 Phase IIIb 63 cytoreductive nephrectomy 63 assessing T DM1 63 Trandolapril 63 prospective observational 63 recurrent malignant glioma 63 Raloxifene STAR 63 ATACAND 63 riociguat 63 demonstrated clinically meaningful 63 Prostate Cancer Prevention 63 EVEREST II 63 SPIRIT FIRST 63 CAMMS# 63 adenoma recurrence 63 Acute Decompensated Heart Failure 63 tolerability pharmacokinetics 63 Prospective Randomized Trial 62 PRECISE 62 GH deficiency 62 Randomized Clinical Trial 62 placebo controlled dose escalation 62 HOPE TOO 62 antiretroviral naïve 62 evaluating Actimmune 62 Ovarian Cancer Screening 62 BENICAR HCT 62 noninferiority 62 BCIRG 62 Eluting 62 pharmacodynamics PD 62 APEX PD 62 recurrent glioblastoma multiforme 62 GISSI 62 Phase IIB 62 Phase III VISTA 62 pharmacokinetic pharmacodynamic 62 prospective multicenter randomized 62 phase IIa 62 multicenter placebo controlled 62 pretransplant 62 MEND CABG II 62 phase IIa clinical 62 HCV RESPOND 2 62 MADIT II 62 NATRECOR ® 62 ASSERT 62 CALGB 62 #:# randomization 62 multicenter Phase III 62 MIST II 62 ASCEND HF 62 Androxal TM 62 placebo controlled Phase III 62 Oral Fingolimod 62 β blockers 62 FDA defined valvulopathy 62 Glucosamine Chondroitin Arthritis 62 Nesiritide 62 Randomized Double Blind 62 prucalopride 62 LUX Lung 62 ENDEAVOR IV 62 ACE Inhibitor 62 randomized multicenter Phase III 62 CIMZIA R 62 antiangiogenic therapy 62 ADVANCE PD 62 TEC #OL 62 ABSORB clinical 62 prospective randomized placebo 62 efavirenz EFV 62 Randomized Controlled Trials 62 DAPT 62 evaluating REVLIMID 62 SORT OUT III 62 Intervention Trial 62 Phase III randomized controlled 62 See CLINICAL PHARMACOLOGY 62 RIO Lipids 62 TQT 62 observational cohort study 62 CALGB # [002] 62 number NCT# ClinicalTrials.gov 62 Active Ulcerative Colitis 62 prospectively stratified 62 Coronary CTA 62 Sorafenib HCC Assessment 62 ILLUSTRATE 62 prospective observational cohort 62 doxorubicin docetaxel 62 EchoCRT 62 Polyp Prevention Trial 62 ENDEAVOR III 62 Sipuleucel T 62 randomized controlled trial 62 multicenter phase 61 Confirmatory Phase 61 AVERROES 61 PERSEUS 61 specified primary endpoint 61 AIM HIGH 61 Liraglutide Effect 61 everolimus eluting stents 61 ToGA 61 nonpharmacologic 61 randomized Phase III 61 multicentric 61 Sibutramine Cardiovascular Outcomes 61 WHEL 61 CLARITY study 61 Pharmacokinetic 61 phase Ib 61 randomized controlled clinical trials 61 pharmacodynamic PD 61 Bioequivalence 61 selenium supplementation 61 Pooled Analysis 61 Phase III ThermoDox 61 Recurrent Glioblastoma 61 refractory prostate cancer 61 atherosclerotic renal artery stenosis 61 designated HVTN 61 Randomized Clinical Trials 61 adjuvant trastuzumab 61 Phase #b/#a clinical 61 Delcath Phase III 61 neoadjuvant 61 Multicenter Phase 61 Unstable Angina 61 pivotal bioequivalence 61 pharmacokinetic PK study 61 Heterozygous Familial Hypercholesterolemia 61 UKPDS 61 MERLIN TIMI 61 TASKi3 61 PROTEGE 61 Degarelix 61 Controlled Trial 61 DEFER 61 venous thromboembolic disease 61 IMPACT IMmunotherapy 61 Carotid Endarterectomy 61 AA Amyloidosis 61 reactogenicity 61 Pharmacodynamics 61 COPERNICUS 61 mg/m2 cohort 61 HIV HCV coinfected 61 Thrombolysis 61 ritonavir boosted 61 NCIC CTG 61 substudy 61 randomized controlled 61 controlled multicenter Phase 61 J Clin Oncol 61 Prospective Multicenter 61 subgroup analyzes 61 SPRYCEL ® 61 SCD HeFT 61 velafermin 61 CUSTOM III 61 double blinded placebo 61 Carotid Stenting 61 canakinumab 61 acute mania 61 Randomized Phase 61 somatostatin analog 61 Phase III AFFIRM 61 pharmacokinetic PK 61 Pivotal Phase III 61 Raloxifene Evaluation MORE 61 LHRH receptor positive 61 LUMINATE 61 trastuzumab emtansine T DM1 61 ZACTIMA 61 noninferior 61 EINSTEIN DVT 61 Non inferiority 61 desvenlafaxine succinate 61 longitudinal observational study 61 MAGE A3 ASCI 61 opioid naive 61 Relapsing Multiple Sclerosis 61 FACIT 61 Initiate Phase II 61 Ziprasidone 61 myocardial revascularization 61 blinded placebo controlled 61 GAMMAGARD 61 PROactive study 61 J Am Coll 61 Hepatotoxicity 60 Combination REOLYSIN R 60 endothelin antagonists 60 controlled multicenter 60 ID NCT# 60 DIRECT Trial 60 Randomized Phase III 60 prostate cancer CaP 60 Pegylated Liposomal Doxorubicin 60 Adjuvant Treatment 60 azilsartan medoxomil 60 randomized controlled trials RCTs 60 Deforolimus 60 VESTASYNC 60 Aggressive Reduction 60 oral prednisolone 60 CINQUIL 60 symptomatic VTE 60 abacavir lamivudine 60 dose proportionality 60 Tipranavir 60 Phase IIIb study 60 randomized Phase 2b 60 BOLDER II 60 catheter occlusion 60 STEP BD 60 XL# SAR# 60 percutaneous vertebroplasty 60 ECASS 60 Maximum Tolerated Dose MTD 60 CHAMPION PLATFORM 60 morphometric vertebral fractures 60 Nilotinib 60 RE LY trial 60 Angiographic 60 Plaque Psoriasis 60 pramlintide metreleptin combination 60 phase IIb clinical 60 keloid scarring 60 #:#-# [029] 60 Adjunctive 60 ascending dose 60 cisplatin gemcitabine 60 Patency 60 viral kinetic 60 multivitamin supplementation 60 Proellex TM 60 Reduce Cardiovascular 60 Randomized Controlled 60 STICH 60 BoNTA 60 ABSORB trial 60 PLCO 60 postoperative chemotherapy 60 Phase III psoriasis 60 MGd 60 melphalan prednisone 60 Alpha Tocopherol Beta Carotene 60 NCCTG N# 60 PEG IFN 60 mITT population 60 EXPAREL ™ 60 Subgroup analyzes 60 relapsing remitting MS RRMS 60 Endarterectomy 60 COSTAR II 60 VICTOR E1 60 Sirolimus eluting 60 concurrent chemoradiation 60 Comorbidity 60 Dalbavancin 60 hematological parameters 60 primary percutaneous coronary 60 Pyridorin 60 CONQUER OB 60 prospectively defined 60 Infarct 60 Current Controlled Trials 60 postmenopausal osteoporotic women 60 pharmacokinetic characteristics 60 Dose Ranging Study 60 Mycophenolate Mofetil 60 Left Ventricular Dysfunction 60 retrospective cohort 60 Relapsing Remitting Multiple Sclerosis 60 CLOTS 60 Prostate Lung Colorectal 60 MVA MUC1 IL2 60 doxorubicin cyclophosphamide 60 BENICAR 60 Oral Insulin Capsule 60 moderate hepatic impairment 60 ONTARGET R 60 analgesic efficacy 60 zonisamide SR 60 Carotid 60 biliary tract cancer 60 dyslipidaemia 60 Vildagliptin 60 nab paclitaxel 60 Ceplene/IL-2 60 Pegylated Interferon 60 neratinib 60 Acute Myocardial Infarction 60 BR.# 60 TAXUS IV 60 Long Term Efficacy 60 randomized controlled Phase 60 Motesanib 60 eluting stent 60 Pharmacokinetic studies 60 APEX AMI 60 angiographically 60 Patients Receiving 60 beta carotene supplementation 60 EDEMA3 60 pharmacodynamic effects 60 Ophena TM 60 prospective randomized 60 Prevent Stroke 60 REMINYL ® 60 Phase #/#a 60 Multicentre 60 Rheos System 60 PARTNER Trial 60 interstitial brachytherapy 60 CTAP# Capsules 60 RSD# oral 60 PROTECT AF 60 prospective longitudinal 60 relapsing multiple sclerosis 59 carotid artery stenting 59 paclitaxel eluting stents 59 SPIRIT III 59 active comparator 59 Vectibix monotherapy 59 metastatic GIST 59 ABCSG 59 Betaferon R 59 Carvedilol 59 Clinical Outcome 59 AVADO 59 Tumor Response 59 Stent Restenosis 59 metastatic neuroendocrine tumors 59 Antiviral Therapy 59 HDL Selective Delipidation 59 Fracture Intervention Trial 59 BEXXAR Therapeutic Regimen 59 Atherosclerotic 59 visceral metastases 59 GERD migraine headaches 59 MEVACOR 59 VICTOR E3 59 invasive candidiasis 59 Enzastaurin 59 Truvada tablets 59 Teriflunomide 59 ALSYMPCA 59 resectable pancreatic cancer 59 Asthma Intervention 59 neoadjuvant treatment 59 Phase 1b clinical 59 ARBITER 6 59 NP2 Enkephalin 59 KRN# 59 TRANSFORMS 59 STOP AF 59 Placebo Controlled 59 undergoing Percutaneous Coronary 59 antiarrhythmic drug 59 aldosterone antagonists 59 strontium ranelate 59 LAB CGRP 59 Severe Sepsis 59 Main Outcome Measure 59 masked placebo controlled 59 anastrazole 59 elective PCI 59 CBLC# 59 Cognitive behavioral 59 divalproex sodium 59 Vascugel ® 59 Tolvaptan 59 Percutaneous Tibial Nerve Stimulation 59 pharmacodynamic parameters 59 undergoing peritoneal dialysis 59 Helicobacter pylori eradication 59 Atomoxetine 59 Study Evaluating 59 chronic myocardial ischemia 59 prostate cancer PCa 59 multicenter 59 clevidipine 59 postoperative AF 59 MYTHOS trial 59 evaluating satraplatin plus 59 FOSRENOL ® 59 prospective cohort 59 OLYMPIA registry 59 HORIZONS AMI trial 59 Percutaneous Coronary Intervention 59 Subgroup Analysis 59 STEALTH C 59 CABANA 59 Secondary endpoints 59 Bivalirudin 59 glatiramer acetate 59 LibiGel Phase III 59 viral kinetics 59 Randomized phase 59 Histopathological 59 Raptiva r 59 ancrod 59 Pharmacokinetic PK 59 Microalbuminuria 59 Chronic Heart Failure 59 evaluating Vectibix 59 PIX# [002] 59 retrospective observational 59 Temsirolimus 59 perioperatively 59 AST ALT 59 sirolimus eluting 59 genotypic resistance 59 NICE SUGAR 59 undergoing elective percutaneous 59 Dose Response 59 Histological 59 CAPRIE 59 teriflunomide 59 posttreatment 59 liposomal amphotericin B 59 Aflibercept 59 urodynamic 59 acyclovir Lauriad R 59 retrospective cohort study 59 Scandinavian Simvastatin Survival 59 Afatinib 59 novel VDA molecule 59 univariate 59 TASKi2 59 Double Blind Randomized 59 RE SURGE 59 APPRAISE 59 IMPACT DCM clinical 59 Aranesp Therapy 59 Acute Coronary Syndromes ACS 59 fallopian tube cancers 59 Adjuvant Breast Cancer 59 laparoscopic fundoplication 59 Carotid Artery Stenting 59 Follicular Lymphoma 59 HuMax EGFr 59 polyarticular 59 NEUVENGE 59 Overactive Bladder OAB 59 TG MV 59 Relieve Depression 59 Anturol TM 59 beta blocker therapy 59 rALLy clinical trial 59 sorafenib Nexavar 59 Phase III randomized 59 dietary modification 59 lorcaserin Phase 59 Cholesterol Levels SPARCL 59 HBeAg negative patients 59 Desvenlafaxine Succinate 59 Nonalcoholic Fatty Liver Disease 59 Myocardial Perfusion 59 NMIBC 59 RCTs 59 Pivotal Trial 59 Outpatient Setting 59 REVIVE Diabetes 59 interpersonal psychotherapy 59 Lipid Lowering Treatment 59 TURBT 59 transrectal ultrasound guided 59 ritonavir boosted lopinavir 59 Pharmacokinetics PK 59 Nonsurgical 59 visit http:/www.clinicaltrials.gov/ 59 paricalcitol 59 tramiprosate Alzhemed TM 59 label multicenter 59 salmeterol fluticasone 59 FOLPI 59 Hormone Refractory Prostate Cancer 59 Treatment Outcome 59 multicentre study 59 IIa clinical 59 Antiplatelet 59 quadrivalent HPV vaccine 59 ZYBRESTAT fosbretabulin 59 metastatic malignant 59 Digital Mammographic Imaging 59 myopic CNV 59 Eluting Stent 59 Acute Ischemic Stroke 59 pegylated interferon alfa 2b 59 preclinical efficacy 59 symptomatic paroxysmal AF 58 PREZISTA r 58 rosuvastatin Crestor 58 Clinical Efficacy 58 hematopoietic cancers 58 Sirolimus eluting Coronary Stent 58 Protease Inhibitors 58 prospective multicenter study 58 urinary N telopeptide 58 boosted protease inhibitor 58 Accelerated Partial Breast Irradiation 58 evaluating carfilzomib 58 OBPM 58 APTIVUS 58 thromboembolic complications 58 Doxil ® 58 AIR CF2 58 BETAS 58 WHIMS 58 mg BID dose 58 Alequel 58 periprocedural MI 58 Tanespimycin 58 Dasatinib 58 efficacy tolerability 58 #-# Full Text 58 candesartan cilexetil 58 Aggressive Drug Evaluation 58 ACTEMRA TM 58 hemostatic efficacy 58 PEGINTRON REBETOL combination 58 Dabigatran etexilate 58 PCPT 58 RAVEL 58 Arimidex Tamoxifen Alone 58 Breast Density 58 ANCHOR trial 58 ongoing Phase 1b 58 PRE SURGE 58 CYT# QbG# 58 Percutaneous vertebroplasty 58 drug eluting stent implantation 58 By JENNIFER LEARN 58 sacral nerve stimulation 58 Tocilizumab 58 Safinamide 58 Metabolic Efficiency 58 #F FDG PET 58 Fulvestrant 58 secondary efficacy endpoints 58 ORENCIA ® 58 blind randomized 58 POISE 58 pharmacokinetics pharmacodynamics 58 SUTENT ® 58 vidofludimus 58 underwent percutaneous coronary 58 Targretin capsules 58 certolizumab 58 Glatiramer Acetate 58 Pharmacokinetic Study 58 colorectal adenoma 58 plasma pharmacokinetics 58 dosage regimens 58 CANCIDAS 58 cetrorelix pamoate 58 PROVENGE ® 58 Flu Cy 58 Natalizumab 58 Traficet EN 58 evaluating MGCD# [002] 58 dual antiplatelet 58 TransVax ™ 58 ENVISION 58 PRECiSE 58 Antihypertensive 58 TMC# r 58 ER CHOP 58 Efficacy Trial 58 trastuzumab Herceptin ® 58 ALISTA 58 multicenter trials 58 rFVIIa 58 Coronary Angiography 58 Stenting Trial 58 Diabetic Foot Ulcer 58 Nebulized 58 CIMZIA ™ 58 CCX# B 58 recurrent glioma 58 olanzapine LAI 58 homocysteine lowering 58 Epirubicin 58 chemoradiation therapy 58 Screening Trial 58 INFERGEN 58 AIR CF1 58 urolithiasis 58 symptomatic hyponatremia 58 FIX HF 5 58 REFLEX 58 Pharmacokinetic parameters 58 NSTE ACS 58 Phase #b/#a 58 #mg dosing 58 Perforomist Inhalation Solution 58 Confirmatory 58 haematologic 58 florbetaben 58 efficacy endpoint 58 placebo controlled studies 58 SYMMETRY trial 58 elective percutaneous coronary 58 pimecrolimus cream 58 blind multicenter 58 evaluating tivozanib 58 inhaled AAT 58 Adalimumab 58 ISRCTN# 58 Schizophrenia Treatment 58 multicenter randomized double 58 prognostic indicators 58 mg kg BID 58 AVN# Phase 58 PreCISe 58 FDG PET imaging 58 #mg/day [001] 58 Neoadjuvant 58 phase IIb 58 Phase III ADT 58 SABCS 58 postexposure prophylaxis 58 serotonin norepinephrine reuptake inhibitor 58 tocilizumab 58 Resynchronization 58 elotuzumab 58 Medidur TM FA 58 Hematologic 58 Randomised controlled trial 58 oral anticoagulation 58 Aryplase 58 randomized 58 Benign Prostatic Hyperplasia 58 PCI ExTRACT TIMI 58 mg administered orally 58 Telithromycin 58 Observational studies 58 migraine prophylaxis 58 RhuDex 58 Vertebroplasty 58 duplex ultrasonography 58 metastatic HRPC 58 Myelodysplastic Syndrome MDS 58 Rosuvastatin 58 crizotinib PF # 58 Unfractionated Heparin 58 JAK Inhibitor 58 Hemodialysis Patients 58 preclinical pharmacokinetic 58 Quinamed 58 metaanalysis 58 steroid refractory 58 SYNERGY Stent 58 nondiabetic patients 58 treatment naïve genotype 58 Dabigatran 58 ORAL Solo 58 PEGylated interferon beta 1a 58 SWOG 58 evaluating mipomersen 58 bolus dose 58 EGS# 58 Ranolazine 58 oral ibandronate 58 transcranial Doppler ultrasound 58 multicenter Phase 58 blind placebo 58 phase Ib clinical 58 mRCC 58 daily Infergen 58 Meets Primary Endpoint 58 Etanercept 58 retinal vein occlusion induced 58 tipranavir ritonavir 58 Arch Neurol 58 limiting toxicity DLT 58 Embolic Protection Device 58 colesevelam HCl 58 carotid IMT 58 NSABP 58 Xelox 58 Stent Thrombosis 58 intratympanic 58 Cloretazine 58 Lofexidine 58 multicenter randomized Phase III 58 comparing XIENCE V 58 Vertos II 58 Diabetes ACCORD 58 hematologic parameters 58 OPCAB 58 subcutaneous methylnaltrexone 58 poststroke depression 58 TRITON TIMI 58 Coronary artery bypass grafting 58 Interferon beta 1a 58 Aplidin R 58 icatibant 58 Silodosin 58 RTOG 58 solithromycin 58 SANTE 58 NATRECOR R 58 Ovarian PLCO Cancer 58 ara C 58 SSRI SNRI 58 Adaptive Radiation Therapy 58 SYNTAX trial 58 guanfacine extended release 58 alvespimycin 58 budesonide foam 58 pharmacokinetic PK profile 58 Phase III Clinical Trial 58 carotid revascularization 58 Dose Escalation 58 induced macular edema 58 Prolongs Survival 58 Sandostatin R 58 CaPSURE 58 dialectical behavioral 58 EVA 3S 58 #:#-# [031] 58 Ophena 58 clinical pharmacology studies 58 Pre RELAX AHF 58 pharmacodynamic properties 58 NAVISTAR R 58 Histologic 58 Contraindications 58 Clinical Evaluation 58 EEG abnormalities 57 antiretroviral naive 57 Phase Ia 57 CONSORT 57 pregabalin Lyrica 57 Initiate Phase 57 OvaRex MAb 57 thromboprophylaxis 57 Plecanatide 57 Arch Intern Med 57 CYPHER Stent 57 Remission Maintenance 57 Hsp# Inhibitor 57 nulliparous women 57 Adverse Event 57 randomized placebo controlled 57 mean ± SEM 57 Non Alcoholic Fatty 57 ERATO 57 serum phosphorous 57 fluoxetine paroxetine 57 ENDEAVOR IV clinical 57 Phase III HEAT 57 Phase Ib IIa clinical 57 Platelet Inhibition 57 GRAVITAS trial 57 Diabetes Interventions 57 Scandinavian Cardiac Outcomes 57 heFH 57 Anticoagulation 57 Multicenter Randomized 57 dual endothelin receptor antagonist 57 antioxidant supplementation 57 sunitinib malate 57 gemcitabine carboplatin 57 paclitaxel poliglumex 57 CLIRS 57 Clinical Outcomes Utilizing Revascularization 57 Cloretazine ® 57 mycophenolate mofetil MMF 57 atazanavir ritonavir 57 ConclusionThis 57 RezularTM 57 RoACTEMRA 57 Phase III Psoriasis 57 anti arrhythmic drug 57 Edwards SAPIEN valve 57 CYT# potent vascular disrupting 57 ORMD 57 platelet inhibitor 57 Cardiopulmonary bypass 57 J Nutr 57 RADIANCE 57 dose dose escalation 57 Symptom severity 57 CLL8 57 GnRH agonist 57 stage IIIb IV 57 prostate carcinoma 57 CUSTOM II 57 Intravascular 57 SPARCL 57 phase III ACCLAIM 57 Zestra R 57 budesonide MMX Phase III 57 Coronary angiography 57 thrombus aspiration 57 comorbid psychiatric disorders 57 plus COPEGUS 57 adjuvant endocrine therapy 57 RRMS patients 57 androgen suppression 57 YONDELIS 57 refractory colorectal cancer 57 PROSTVAC VF 57 landmark ATHENA trial 57 Corticosteroid 57 gadobutrol 57 FASLODEX 57 pharmacodynamics 57 transesophageal 57 Pivotal Study 57 AOD# [002] 57 ISAR TEST 57 electrophysiologic 57 Heart Failure Patients 57 Abatacept 57 venlafaxine XR 57 DermaVir Patch 57 naïve HCV 57 Dyloject TM 57 midstage clinical